AAD VMX 2021: Maskne: Side Effects Of Facial Masks During COVID-19
A side effect that might not be the first to think about in the COVID-19 pandemic concerns wearing...
Read MoreApr 26, 2021
A side effect that might not be the first to think about in the COVID-19 pandemic concerns wearing...
Read MoreApr 26, 2021
Presented by: Jules Lipoff (University of Pennsylvania), Elizabeth Jones (Thomas Jefferson...
Read MoreApr 26, 2021
The importance of sunscreen has been acknowledged globally. Recent topics of discussion include...
Read MoreApr 20, 2021
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI) and the support of dedicated multidisciplinary teams (MDTs). While decisions...
Read MoreApr 16, 2021
For patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)...
Read MoreApr 16, 2021
Due to the COVID-19 pandemic, the 2021 American Academy of Neurology Annual Meeting, the world’s premier neurology meeting, will be held in a fully virtual format from April 17-22. It will include: Over 90 expert-led CME...
Read MoreApr 16, 2021
Cognitive impairment is a common and disabling feature of multiple sclerosis (MS), but a precise characterization of cognitive phenotypes in MS patients is still lacking. This study identified five cognitive phenotypes:...
Read MoreApr 16, 2021
The study team compared disability accrual in primary and secondary progressive multiple sclerosis (PPMS, SPMS) in the international MSBase cohort, using multivariable survival models, and applying objective diagnostic criteria...
Read MoreApr 16, 2021
Patients with MS may have difficulty performing double task (DT) while walking or causing interference. More research is needed in order to define the role of disability degree in the severity of the interference produced in the...
Read MoreApr 16, 2021
Management of patients with multiple sclerosis (MS) in the era of disease modifying therapies (DMT) relies heavily on magnetic resonance imaging (MRI). As physicians, decisions are influenced by the reporting prowess of...
Read MoreApr 16, 2021
Five-month advantage observed with tebentafusp The novel bispecific fusion protein tebentafusp...
Read MoreApr 14, 2021
Disease progression slowed with copanlisib/rituximab combo The combination of copanlisib plus...
Read MoreMar 19, 2021
Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study. MET signaling is a key molecular driver in papillary renal cell...
Read MoreMar 19, 2021
Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101 In the phase III JAVELIN Renal 101...
Read MoreMar 19, 2021
Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Using the IMDC dataset, patients treated with a 1L...
Read MoreMar 19, 2021
TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. The TIVO-3 study enrolled subjects with mRCC who failed two or three prior systemic regimens, one of...
Read MoreMar 19, 2021
Enfortumab vedotin (EV) will likely become the new standard of care for treating patients with previously treated locally advanced or metastatic urothelial carcinoma (la/mUC). A recent phase 3 trial showed that treatment with...
Read MoreMar 19, 2021
Although the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated superiority in progression-free survival (PFS) and overall...
Read MoreMar 19, 2021
Test your knowledge on results on PsA released at ACR Convergence 2020 – take our quiz and...
Read MoreMar 17, 2021
In the phase 3 multicenter, open-label, randomized CLEAR trial, lenvatinib in combination with pembrolizumab or everolimus demonstrated significant benefits over sunitinib in patients with advanced renal cell carcinoma (RCC)....
Read More